Loss of SETD2 function has been investigated in several human tumours, including GI stromal tumours, renal cell carcinoma, pancreatic ductal adenocarcinoma (PDAC), prostate cancer, breast cancer, leukaemia and high‐grade gliomas.23, 24, 25, 26, 27, 28, 29. Here, SETD2 is linked to neoplasm.